Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Uveitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    114 result(s) found for: Uveitis. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2006-001732-53 Sponsor Protocol Number: ADUR-Studie Start Date*: 2006-08-16
    Sponsor Name:University Hospital of Heidelberg
    Full Title: Eine multizentrische, randomisierte, kontrollierte Studie zur Untersuchung von Adalimumab bei der Behandlung verschiedener Formen von refraktärer Uveitis im Vergleich zur Standardtherapie Randomiz...
    Medical condition: Adalimumab in treatment of refractory uveitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001610-42 Sponsor Protocol Number: X052130/CL3-78989-005 Start Date*: 2013-01-24
    Sponsor Name:XOMA (US) LLC
    Full Title: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    17.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    17.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    17.0 100000004862 10036370 Posterior uveitis LLT
    17.0 10015919 - Eye disorders 10066681 Acute uveitis LLT
    17.0 100000004866 10071139 Behcet's uveitis LLT
    17.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    17.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    17.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Completed) GB (Prematurely Ended) ES (Completed) GR (Prematurely Ended) AT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004973-29 Sponsor Protocol Number: CL3-78989-019 Start Date*: 2014-08-13
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.
    Medical condition: chronic non-infectious uveitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10022557 Intermediate uveitis LLT
    18.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    18.0 100000004862 10036370 Posterior uveitis LLT
    18.0 100000004866 10071139 Behcet's uveitis LLT
    18.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    18.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    18.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed) PT (Completed) ES (Completed) AT (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003612-53 Sponsor Protocol Number: LIGS4001 Start Date*: 2008-07-25
    Sponsor Name:National Institutes of Health, National Eye Institute
    Full Title: Multicenter Uveitis Steroid Treatment Trial
    Medical condition: Non-infectious uveitis (inflammatory eye disease)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046851 Uveitis LLT
    9.1 10033687 Panuveitis LLT
    9.1 10022557 Intermediate uveitis LLT
    9.1 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001609-25 Sponsor Protocol Number: X052131/CL3-78989-006 Start Date*: 2013-01-02
    Sponsor Name:XOMA (US) LLC
    Full Title: A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Subjects with Non-infectious IntermeDiate, Posterior, or Pan- uveitis Currently C...
    Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    17.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    17.0 100000004862 10036370 Posterior uveitis LLT
    17.0 100000004866 10071139 Behcet's uveitis LLT
    17.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    17.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    17.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) PT (Completed) IT (Completed) GR (Prematurely Ended) ES (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006728-20 Sponsor Protocol Number: TAYS1002 Start Date*: 2007-05-31
    Sponsor Name:Moorfields Eye Hospital
    Full Title: The use of intraocular methotrexate to treat uveitis: a safety and efficacy study
    Medical condition: Uveitis (inflammatory eye disease)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004160-30 Sponsor Protocol Number: CFTY720D2205 Start Date*: 2013-05-08
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A multicenter, randomized, active-controlled study to assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis
    Medical condition: Uveitis, intermediate; uveitis, posterior; uveitis, pan.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016196-29 Sponsor Protocol Number: M11-327 Start Date*: 2010-07-19
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Medical condition: Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022557 Intermediate uveitis LLT
    12.1 10033687 Panuveitis LLT
    12.1 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001078-25 Sponsor Protocol Number: H.34.04.04.07.B1 Start Date*: 2011-11-07
    Sponsor Name:National Institute of Health, National Eye Institute
    Full Title: Long-term Follow-up of Patients Who Participated in the Multicenter Uveitis Steroid Treatment Trial (MUST Trial Follow-up Study).
    Medical condition: Non-infectious pan, intermediate and posterior uveitis (inflammatory eye disease)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    14.0 10015919 - Eye disorders 10046851 Uveitis PT
    14.0 10015919 - Eye disorders 10036370 Posterior uveitis LLT
    14.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004876-10 Sponsor Protocol Number: ASF-EVER.1 Start Date*: 2007-08-06
    Sponsor Name:Department of Ophthalmology at St. Franziskus Hospital
    Full Title: single center study on safety and efficacy of everolimus in patients with endogenous intermediate and posterior uveitis
    Medical condition: Uveitis, specially endogenous interemdiate and posterior uveitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016008-22 Sponsor Protocol Number: M10-880 Start Date*: 2010-07-19
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Medical condition: Inactive non-infectious intermediate-, posterior-, or pan-uveitis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022557 Intermediate uveitis LLT
    12.1 10033687 Panuveitis LLT
    12.1 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) NL (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-016095-68 Sponsor Protocol Number: M10-877 Start Date*: 2010-07-19
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non infectious...
    Medical condition: Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022557 Intermediate uveitis LLT
    12.1 10033687 Panuveitis LLT
    12.1 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) NL (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-001589-15 Sponsor Protocol Number: BLP 415-007 Start Date*: 2005-09-15
    Sponsor Name:Bausch & Lomb Incorporated
    Full Title: A multi-center study evaluating the safety of a replacement intravitreal fluocinolone acetonide (FA) (0.59 mg) implant in patients with non-infectious posterior uveitis who were previously treated ...
    Medical condition: Non-infectious Uveitis affecting posterior segment of the eye
    Disease: Version SOC Term Classification Code Term Level
    4.1 10036370 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003689-24 Sponsor Protocol Number: PAVC1012 Start Date*: 2009-04-29
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: Lotemax in the treatment of chronic anterior uveitis: a pilot study
    Medical condition: Chronic Anterior Uveitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002709 Anterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006545-13 Sponsor Protocol Number: LX211-03-UV Start Date*: 2007-04-27
    Sponsor Name:Lux Biosciences GmbH
    Full Title: A Double-Masked, Placebo-Controlled, Multi-Centre, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Uveitis.
    Medical condition: Subjects with active sight-threatening, non-infectious anterior, anterior and intermediate- or panuveitis who require systemic immunosuppression for the control of their disease.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004845-34 Sponsor Protocol Number: ACT13480 Start Date*: 2013-09-02
    Sponsor Name:Sanofi-aventis recherche et développement
    Full Title: A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients with Non-Infectious, Intermediate, Po...
    Medical condition: Uveitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003254-90 Sponsor Protocol Number: CLFG316A2204 Start Date*: 2012-05-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomised, active-controlled, open-label, multiple-dose, proof-of-concept study of intravitreal LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveitis requiring s...
    Medical condition: Active non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000161411 10022557 Intermediate uveitis LLT
    20.0 100000014975 10033687 Panuveitis LLT
    20.0 100000015065 10036370 Posterior uveitis LLT
    20.0 100000014975 10066681 Acute uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001243-67 Sponsor Protocol Number: CAIN457A2208 Start Date*: 2011-07-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label proof-of-concept study with a double-masked, dose-ranging component to assess the effects of AIN457 in patients with noninfectious uveitis
    Medical condition: Intermediate, posterior or pan-uveitis of noninfectious origin
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    14.0 10015919 - Eye disorders 10036370 Posterior uveitis LLT
    14.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006543-31 Sponsor Protocol Number: LX211-01-UV Start Date*: 2007-04-13
    Sponsor Name:Lux Biosciences GmbH
    Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight ...
    Medical condition: Subjects with active sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004899-50 Sponsor Protocol Number: 2200/07 Start Date*: 2008-05-13
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: OCT analysis of cystoid macular edema in uveitis patients undergoing anti-inflammatory treatment
    Medical condition: Cystoid macular edema in uveitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051240 Cystoid macular edema LLT
    9.1 10046851 Uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 22:01:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA